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Abstract: It is increasingly acknowledged that delays in the diagnosis of chronic inflammatory 
lung conditions have hampered our understanding of pathogenesis and thus our ability to design 
efficacious therapies. This is particularly true for COPD, where most patients are diagnosed with 
moderate-to-severe airflow obstruction and little is known about the inflammatory processes 
present in early disease. There is great interest in developing screening tests that can identify those 
most at risk of developing COPD before airflow obstruction has developed for the purpose of 
research and clinical care. Landmark pathology studies have suggested that damage to the small 
airways precedes the development of airflow obstruction and emphysema and, thus, presents 
an opportunity to identify those at risk of COPD. However, despite a number of physiological 
tests being available to assess small airways function, none have been adopted into routine 
care in COPD. The reasons that tests of small airways have not been utilized widely include 
variability in test results and a lack of validated reference ranges from which to compare results 
for some methodologies. Furthermore, population studies have not consistently demonstrated 
their ability to diagnose disease. However, the landscape may be changing. As the equipment 
that delivers tests of small airways become more widely available, reference ranges are emerging 
and newer methodologies specifically seek to address variability and difficulty in test perfor-
mance. Moreover, there is evidence that while tests of small airways may not be helpful across 
the full range of established disease severity, there may be specific groups (particularly those 
with early disease) where they might be informative. In this review, commonly utilized tests of 
small airways are critically appraised to highlight why these tests may be important, how they 
can be used and what knowledge gaps remain for their use in COPD.
Keywords: small airways, COPD, early disease, physiology, emphysema, airflow obstruction
Introduction
The small airways (usually defined as those with an internal diameter of #2 mm) are 
recognized as the major site of resistance to airflow in obstructive lung disease. The 
direct physiological support for this came from the classical study of Hogg et al,1 
and subsequent pathological studies confirmed a generalized decrease in diameter 
of the small airways in smokers with established airflow obstruction.2 However, it 
was recognized that pathological changes in the small airways, although related to 
expiratory airflow obstruction,3 could occur in the absence of spirometric impairment 
that is diagnostic of COPD. This led to the concept of small airways representing the 
“silent zone” of lung disease (the site of early lung damage without recognized airflow 
obstruction or, necessarily, symptoms), which, in turn, led to the development and 
validation of new physiological tests aimed at detecting abnormalities in peripheral 
airways and the associated resistance to airflow. Such tests were developed to explore 
the concept of “early disease”, and it was argued that they could identify subjects at 
risk of future development of COPD. Indeed, some studies provided evidence sup-
porting this concept,4 whereas others reported the opposite.5,6 These results, therefore, 
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questioned the utility of the tests in subject assessment and 
prognosis, which hindered their general usage.
In recent years, there has been a resurgence of interest in 
the study of small airways from a pathophysiological view-
point and even for clinical management. The ability to phe-
notype patients with COPD in more detail has led to further 
interest in the emphysematous lung. Emphysema is associ-
ated with both airflow obstruction and, importantly, a more 
rapid subsequent decline in the forced expiratory volume in 
one second (FEV
1
),7,8 increased mortality9 and prevalence of 
lung cancer.10 The more comprehensive pathological studies 
reported by Hogg and colleagues11,12 have highlighted (albeit 
cross-sectionally) evidence that significant loss of small air-
ways also precedes the pathological evidence of emphysema. 
In support of this concept, a recent study in alpha-1 antitrypsin 
deficiency (AATD), which is an emphysema-dominant COPD 
phenotype, found maximal mid-expiratory flow (MMEF) 
(as a surrogate of small airways function) preceded both the 
spirometric evidence of COPD and detection of emphysema 
by computed tomography. In addition, abnormal tests were 
associated with impaired health status and predicted the sub-
sequent rate of decline of FEV
1
.13
Detecting early physiological abnormality in the small 
airways is challenging for a number of reasons. First, while 
the majority of tests available may be affected by small airway 
dysfunction, they do not necessarily assess the small airways 
exclusively and may also be influenced by abnormality in 
the larger airways. For instance, measures of global airway 
resistance (Raw) may be influenced by increased resistance 
of the small or large airways. Furthermore, abnormality (such 
as obstruction) in the larger airways may render the small 
airways less accessible with physiological testing. Second, 
due to the vast number of small airways, a widespread dys-
function may be required before physiological abnormality 
is detectable. Finally, unlike routine lung function tests (such 
as spirometry and gas transfer), many physiological tests of 
small airway function do not currently have robust reference 
ranges, making it more difficult to define “abnormality”. 
It is also important to differentiate between small airways 
disease (specific pathology), small airways dysfunction 
(quantifiable physiological abnormality) and early disease 
(early pathological changes that may or may not occur in 
the small airways).
As with all chronic diseases, early detection and develop-
ment of preventative strategies is important in the preven-
tion or abrogation of the long-term sequelae and health care 
consequences of COPD. The use of validated and robust 
tests of small airways function will likely play a key role in 
this strategy. Therefore, the purpose of the current review 
is to explore the role of previous and newer tests of small 
airways function, their potential strengths and weaknesses 
in identifying subjects at risk of developing COPD and 
their use/proposed use in patient monitoring and response 
to treatment.
Spirometry
Spirometry is an assessment of pulmonary ventilation and 
currently defines the presence of COPD with a reduction 
in the FEV
1
/forced vital capacity (FVC) ratio according to 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) strategy document.14 It is the most widely used 
and accessible lung function test, and the FEV
1
 is the most 
common parameter used prognostically for monitoring and 
as a primary outcome for interventional trials in COPD. 
Although spirometry provides robust information about 
established pathology and its progression, routine spirometric 
parameters are of limited value, especially in early disease. 
For example, spirometry is recognized as a poor surrogate 
for emphysema, which may be present even when the FEV
1
 
and FVC are within the normal range.15 As small airways 
disease has also been shown to precede the development 
of emphysema,16 this supports the concept that routine 
spirometry would be insensitive to early changes in the small 
airways as the pathological processes of COPD develop.
Expiratory flows
Early airway changes in COPD most commonly occur in the 
peripheral regions of the lungs at the level of the terminal 
bronchioles.1 Throughout the expiratory curve, flow measure-
ments may be taken at different intervals that reflect airflow 
through different airways. These include maximal expiratory 
flow when 75% of FVC remains (MEF
75
), maximal expira-
tory flow when 50% of FVC remains (MEF
50
), maximal 
expiratory flow when 25% of FVC remains (MEF
25
) and the 
MMEF (between 75 and 25% of FVC) (Figure 1).
Leuallen and Fowler17 first introduced the MMEF as a 
test of ventilation that was particularly sensitive to expira-
tory airflow obstruction. This parameter has been the most 
widely studied to date. Recently, Tsushima et al18 described 
a significantly lower percentage predicted MMEF in GOLD 
Stage 0 COPD (patients “at risk” of COPD who are symp-
tomatic but have a normal FEV
1
/FVC) than in healthy 
(asymptomatic) subjects. MMEF/FVC has also been found 
to be lower in these patients considered at risk of COPD than 
in healthy individuals, although higher than in those with 
established COPD.19
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Small airways disease
However, it should be noted that MMEF is highly depen-
dent on FVC and may, therefore, be reduced in the absence 
of airflow limitation when a patient’s lungs are smaller than 
average for their age, sex, height and race. Therefore, MMEF 
requires cautious interpretation, and as such, its usefulness 
in general clinical practice has generally been discounted.20 
For serial measurements, it has been suggested that the 
dependency of MMEF on FVC may be overcome by mea-
suring it iso-volumetrically (at the same lung volume),21,22 
although this requires more specialized equipment. However, 
despite the limitations of MMEF, it may still be useful as a 
stand-alone measure in certain patient cohorts as a marker of 
early airflow limitation before the spirometric criterion for 
COPD is reached.13,23 Topalovic et al23 extended this concept 
by analyzing the shape of the flow-volume curve and demon-
strated that the angle of inflection between the two best fitting 
regression lines of the expiratory curve with a cutoff angle 
of ,131° was highly specific (97%), although less sensitive 
(51%), for the presence of emphysema in COPD. This angle 
of inflection (or “spirographic kink”) reflects the dynamic 
airways collapse due to the loss of lung connective tissue in 
emphysema (notably elastin) that usually maintains airway 
patency during forced expiration in healthy individuals.24,25
An alternative approach has been proposed to compare 
the FVC (a forced maneuver) with a relaxed vital capacity 
(VC) maneuver, which overcomes (at least partly) the 
dynamic airways collapse associated with damaged small 
airways and supporting connective tissue loss. Barros et al26 
assessed this by measuring the difference between VC and 
FVC in 1,084 individuals who underwent spirometry and 
plethysmography. The authors observed a higher difference 
(VC−FVC) in patients who had airflow obstruction than in 
“healthy” individuals (140.9 mL ±9.20 vs 79.3 mL ±7.61, 
respectively, P,0.001). Whether such a difference can be suf-
ficiently discerning in the absence of physiologically defined 
COPD remains to be determined. However, a further study 
has suggested that a reduced FEV
1
 in the presence of normal 
FEV
1
/VC ratio may also reflect airflow limitation in the small 
airways,27 although further validation is clearly necessary.
Single breath washout
The concept of early closure of the small airways during 
exhalation has been exploited in the past by observing the 
gas composition during different stages of a total expiration. 
The single breath washout test is performed by inhaling 100% 
oxygen from residual volume (RV) to total lung capacity 
(TLC), then expiring slowly (0.4–0.5 L/s) to RV again.28 
Analysis of the nitrogen concentration throughout this expi-
ration is quadriphasic, with Phase I containing negligible 
nitrogen (anatomical dead space), Phase II involving a short 
rapid increase in nitrogen (bronchial phase), Phase III involv-
ing a continued, more gradual rise in nitrogen (alveolar phase) 
and Phase IV involving a short final rapid rise in nitrogen 
(airway closure). Closing volume (CV) is the volume of gas 
left to expire when peripheral airway closure begins.29 If RV 
is known, the closing capacity (CC), which is the volume 
of gas remaining in the lungs and airways at this point, can 
also be calculated as the sum of RV and CV. A typical plot 
of expired gas versus volume is shown in Figure 2.
In healthy adults, CV occurs at low lung volumes (shortly 
before the endpoint of expiration) as a result of gravity-
dependant pleural pressure.28 In obstructive lung disease, 
CV is increased due to premature airway closure, which can 
occur for several reasons (including loss of elastic recoil as 
part of the emphysema process and loss/occlusion of small 
airways). It has previously been shown that, by comparing 
the kinetics of different inert gases, patients with advanced 
emphysema can be distinguished from healthy individuals 
and those with other respiratory diseases (eg, asthma) by a 
differential Phase II (a more pronounced separation of helium 
and sulfur hexafluoride).30 In early disease, however, most of 
the GOLD Stage 0 smokers exhibit increased Phase III slope, 
with further progressive increases from GOLD Stages I–IV,31 
suggesting that the analysis of this phase may be a more useful 
Figure 1 Graphical representation of a flow-volume loop indicating the traditional 
parameters (Fev1 and FVC) and the various flow parameters measured at intervals 
throughout the forced expiratory curve.
Abbreviations: Fev1, the forced expiratory volume in one second; FvC, forced vital 
capacity; MMEF, maximal mid-expiratory flow; MEF25, maximal expiratory flow when 
25% of FvC remains; MeF50, maximal expiratory flow when 50% of FVC remains; 
MeF75, maximal expiratory flow when 75% of FVC remains; PEF, peak expiratory flow.
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indicator of airway pathology before overt COPD develops. 
Buist and Ross32 recorded abnormal CV measurements (in 
relation to VC) in 44% of male and 36% of female smokers, 
whereas FEV
1
 was abnormal in only 12% of both sexes. CV 
increases disproportionately with age in smokers,33 suggesting 
that it is a sensitive indicator of small airways damage. This 
theory has been further supported by more recent studies that 
show CV not only correlates with FEV
1
/FVC34 but is also a 
more sensitive test of early lung damage than FEV
1
.35
Recently, a new method of assessing single breath wash-
out during tidal breathing has been developed.36 The test is 
based on the differential distribution of the two inhaled tracer 
gases (helium and sulfur hexafluoride). The outcome is a 
“tidal Phase III slope”, and subsequent studies demonstrated 
that it has good reproducibility in the limited cohorts of 
healthy individuals and patients with COPD studied37 and it 
is a sensitive marker of small airways function in moderate-
to-severe COPD.38 However, the test and its interpretation are 
still in development and further validation will be required 
before it can be implemented and interpreted clinically.
Multiple breath washout
The measurement of lung volumes by multiple breath 
washout was first described .50 years ago39 and involves 
the washout of an inert tracer gas (typically nitrogen or 
sulfur hexafluoride) by breathing 100% oxygen during 
relaxed, tidal ventilation. The lung clearance index (LCI) 
is calculated by dividing the functional residual capacity 
(FRC) by the cumulative expired volume (the total volume 
of expired gas during the test). LCI is an assessment of 
ventilation heterogeneity and, consequently, increases with 
the severity of airflow obstruction. LCI has shown to be a 
sensitive and repeatable measure of airways disease,40–42 and 
importantly, Kraemer et al43 demonstrated that it was the first 
of many lung function parameters (including the traditional 
tests) to decline in children with cystic fibrosis, supporting 
its value in detecting early anatomical change. However, the 
usefulness of LCI in COPD has yet to be fully explored.
Analysis of the Phase III slope of the multiple breath wash-
out curve represents intrinsic airway structure.44,45 It allows the 
determination of differentiation of ventilation heterogeneity 
between the larger, conducting airways (S
cond
) and, impor-
tantly, the small airways in the acinar region (S
acin
). Studies 
have demonstrated that both S
cond
 and S
acin
 are increased in 
established COPD46 but can also detect small airway abnor-
malities at the acinar entrance in patients with a lower smoking 
history ($10 pack years) than spirometry ($20 pack years). 
Other studies in asthma47 and bronchiolitis obliterans syn-
drome48 suggest that S
acin
 may be a useful physiological marker 
of small airways function. However, its sensitivity to early 
small airways pathology is controversial, as one recent study 
demonstrated that S
acin
 only became significantly higher than 
in never-smokers or smoking control subjects once GOLD 
Stage II COPD had developed (although the results of the 
GOLD Stage I cohort may have been underpowered).49
Although multiple breath washout tests are non-voli-
tional, they are far more time consuming than single breath 
techniques, particularly when a tracer gas must first be 
washed into the lungs before being washed out (as with sulfur 
hexafluoride). Another challenge is the standardization of 
techniques, as different tracer gases have different physical 
properties and wash out of the lungs at different rates, 
yielding different results.50 Nevertheless, multiple breath 
washout tests are already widely implemented clinically for 
cystic fibrosis51 and a recent study has also shown that LCI 
may also be clinically useful as an indicator of early disease 
in AATD before spirometry becomes abnormal.52
Airways resistance
Spirometry has been generally considered as the gold stan-
dard method by which abnormal airflow limitation is diag-
nosed and assessed. However, the development of airflow 
limitation is multifactorial and an increase in Raw by direct 
measurement can potentially provide further information on 
airway function. Raw is measured by body plethysmography 
and relates airflow to driving pressure during tidal ventilation, 
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Figure 2 A typical plot of exhaled volume versus nitrogen concentration (N2 %) 
obtained during the single breath nitrogen washout test.
Note: Stages I–Iv (including the Phase III slope) are indicated, and the volume 
relationship between Cv, CC, Rv and TLC is also shown.
Abbreviations: CC, closing capacity; Cv, closing volume; Rv, residual volume; 
TLC, total lung capacity.
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Small airways disease
although it is not routinely reported or used for interpretation. 
Raw is measured in conjunction with a technically demanding 
measurement of thoracic gas volume (TGV).53–56 In contrast, 
specific Raw (sRaw) can be obtained during non-volitional 
tidal ventilation. sRaw is derived from the specific resistance 
loop using a line of best fit (specific effective resistance 
[sReff]), the line connecting the maximum difference in shift 
volume (specific total resistance [sRtot]) or, less commonly, 
the line connecting expiratory flow between 0.5 and −0.5 L/s. 
In healthy individuals (where the sRaw loop is linear), these 
three parameters are essentially equivalent, but in airflow 
obstruction, hysteresis of the sRaw loop leads to differences 
in sReff, sRtot and specific resistance at the flow of 0.5 litres 
per second (sR0.5) (Figure 3). Both sReff and sRtot are estab-
lished measures of Raw,57,58 and one recent study in COPD 
suggested that both are reliable measures of peripheral airway 
function that relate to symptoms of dyspnea.59
The inverse of sRaw is specific airway conductance 
(sGaw), which is often considered as a more robust measure 
than Raw or sRaw due to its linear relationship with lung 
volume.60 Studies of Raw/conductance in COPD are also 
limited, although one early study demonstrated a marked 
reduction in Raw and sGaw in AATD patients with physiolog-
ically established airflow obstruction.61 Furthermore, sGaw is 
significantly reduced in chronic heavy smokers before airway 
obstruction is demonstrable by spirometry,62 again support-
ing airway changes undetected by conventional tests in early 
(or “pre”) COPD. In addition, one study demonstrated that 
sGaw decreased before FEV
1
 in post-transplant bronchiolitis 
obliterans syndrome, leading to support that sGaw is a more 
sensitive measure of small airways dysfunction than FEV
1
.63 
However, plethysmographic measures of Raw/conductance 
may be affected by airflow limitation anywhere in the respi-
ratory tract and the evidence for usefulness of these param-
eters as a marker of small airways function in early COPD 
is uncertain. For example, it has also been shown that sRaw 
does not increase significantly (compared to people with 
normal spirometry) until moderate (GOLD Stage II) airflow 
obstruction has developed in AATD (Figure 4).64
Oscillometry
The forced oscillometry technique (FOT) and impulse oscil-
lometry (IOS) are entirely non-volitional methods for assess-
ing airway impedance (pressure/flow signal) by emitting 
oscillatory pressures of different frequencies (commonly 
between 5 and 35 Hz) into the respiratory tract during tidal 
ventilation. The different frequencies allow for indepen-
dent assessment of both proximal and peripheral airway 
mechanics.65–67 Higher frequencies (eg, 20 Hz) do not 
penetrate deeply and relate to proximal airway function, 
whereas lower frequencies (eg, 5 Hz) penetrate further and 
also include peripheral airway function. Consequently, the 
difference in resistance measurements (R5–R20) has been 
used as a surrogate marker to define peripheral Raw. The 
reactance at 5 Hz (X5) assesses the structural properties 
(inertia and capacitance) of the peripheral lung parenchyma 
and changes concordantly with variations in elasticity.65,66,68–70 
The resonant frequency (Fres) is the frequency (Hz) at which 
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Figure 3 A typical sRaw loop in a patient with airflow obstruction, where shift 
volume is plotted against airflow.
Note: Hysteresis due to airflow obstruction highlights the differential derivation of 
sRaw using the sReff, sRtot and sR0.5 methods in these patients.
Abbreviations: sRaw, specific airway resistance; sReff, specific effective resistance; sRtot, 
specific total resistance; sR0.5, specific resistance at the flow of 0.5 litres per second.
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Figure 4 sRtot percentage predicted in 254 AATD patients with normal spirometry 
and varying degrees of airflow obstruction: mild (GOLD Stage I), moderate (GOLD 
Stage II), severe (GOLD Stage III) and very severe (GOLD Stage Iv).
Note: *Significantly different from patients with normal spirometry (P,0.001).
Abbreviations: AATD, alpha-1 antitrypsin deficiency; GOLD, the Global Initiative 
for Chronic Obstructive Lung Disease; sRtot, specific total resistance.
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reactance is zero (when inertia and capacitance are equal). 
Importantly, X5 correlates well with more traditional mea-
sures of lung function such as spirometry.71
The ability to isolate peripheral airway function by using 
an effort-independent method is of importance, as it not only 
assesses the small airways but also is independent of effort-
related patient variability. Studies indicate that IOS not only 
is a useful measure of small airway function in COPD72–74 
but may also be more sensitive to early COPD than spirom-
etry both cross-sectionally75 and longitudinally.71 Interest 
in FOT (the original oscillometry technique) has recently 
increased with the development of both greatly improved 
FOT technology and a more robust normal reference range.76 
Newer devices also allow the differentiation of inspiratory 
and expiratory mechanics, while including other parameters 
such as expiratory flow limitation. Studies with modern FOT 
devices have shown that they may be sensitive to very early 
smoking-induced small airway changes77,78 and useful for 
prospective monitoring in COPD.79
Therefore, the evidence that FOT can accurately isolate 
small airways function is promising but has yet to be fully 
evaluated, particularly as a marker of small airways dysfunc-
tion in early COPD. However, the clinical usefulness of FOT 
has been demonstrated in a number of studies where it has 
helped differentiate between COPD and asthma80 and has 
provided a clinically valuable means of monitoring changes in 
the small airways more sensitively than spirometry, following 
bronchial challenge81 or bronchodilator therapy.82 FOT may 
also be a useful and more appropriate tool for monitoring 
COPD patients during exacerbation83,84 and following airway 
clearance therapy.85 Further support for FOT as a useful physi-
ological tool in clinical practice has been highlighted in recent 
clinical trials of bronchodilator therapy in COPD.86
Computed tomography
Computed tomography is being increasingly explored in 
understanding the clinical phenotype, pathophysiology and 
progression of COPD. It is the most direct, noninvasive way 
to assess the presence, type and distribution of emphysema. 
This is based on the loss of tissue and dilation of alveolar 
airspaces as a part of the emphysema process, which results in 
a reduction in lung density that can be quantified by objective 
analysis of the density data from the scanner. As emphysema 
develops and progresses, lung density measured at full inspi-
ration reduces, closer to the density of air. Pathological studies 
have shown that emphysema is related to regions of the lung 
where density is ,−950 hounsfield units (HU).87 The presence 
of emphysema relates to both the subsequent rate of decline 
of FEV
1
7,8 and mortality.9 Furthermore, the progressive 
loss of density is the most direct and sensitive measure of 
emphysema progression88 and, for this reason, has been 
included as the primary outcome for several interventional 
studies to study disease-modifying therapies.89–91
Landmark pathological studies with high radiation dose 
micro-computed tomography (CT) analysis have provided 
evidence that the loss of small airways is an early event pre-
ceding the development of emphysema. With the continuing 
development of CT analysis, there have been several recent 
publication investigating the ability of CT to determine the 
presence of small airways disease and accurately quantify 
it. This is based on the concept that excess air trapping on 
expiration is a result of loss or premature closure of the small 
airways. Thus, on a scan performed at full expiration (RV), 
low density lung voxels (,−856 HU) identify incomplete 
emptying of the lung. In contrast, low density lung voxels 
(,−950 HU) on a scan performed at full inspiration (TLC) 
identify areas of emphysema. Analysis of inspiratory and 
expiratory CT data by parametric response mapping (PRM) 
can, therefore, potentially quantify air trapping due to small 
airways disease.
Although this concept seems reasonable, validation is 
urgently required to provide confidence that this methodology 
is both specific to the small airways and reproducible. For 
instance, in the publication by Bhatt et al,92 the expiratory 
scan was measured at FRC rather than RV, which will still 
contain low attenuation areas that are, at least in part, dilated 
air spaces due to emphysema and not the sole result of air 
trapping due to loss/closure of small airways that would be 
best identified and quantified at RV. Furthermore, achieving 
and maintaining the breath at RV reproducibly for initial 
and follow-up scan is difficult, especially in the presence 
of established COPD. This is demonstrated in a study by 
Sieren et al,93 where the average change in RV determined 
by volumetric analysis of scans from 952 subjects at base-
line and 1 year later was +35 mL on average but with an SD 
of ±470 mL. This enormous variation was seen despite careful 
methodology, the use of phantoms, adjustment for body mass 
index and standardized patient instructions. The variation was 
also noted to be extreme more frequently than scans at TLC. 
Nevertheless, in a recent follow-up publication by Martinez 
et al94 of 580 never- and ever-smokers with normal spirom-
etry, there was an age-dependent increase in the PRM indica-
tive of small airways disease that would be consistent with 
the concept of the “aging lung”. How this differs from the 
“premature aging” of the early pathological and physiological 
changes of the COPD lung remains to be determined.
Small airway function has also been assessed in asthma 
using an alternative CT technique. Vos et al95 used a computer 
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model to reconstruct a 3D image of the small airways 
(1–2 mm) at both TLC and FRC. By calculating the differ-
ence in small airway volume from TLC to FRC, the internal 
airflow and, hence, small Raw was derived. It is worth 
noting that this technique did not allow the assessment of 
airways ,1 mm in diameter, so inclusion of all small airways 
was not possible. However, it seems logical that it could also 
be used in COPD as a useful method of assessing (at least in 
part) small airway function.
These studies, although interesting, clearly need more vali-
dation of data acquisition and longitudinal studies to determine 
any clinical usefulness as well as the complex analysis and 
radiation exposure to patients that may limit the usefulness and 
generalizability. If CT techniques (particularly PRM) do prove 
robust, it would allow the relationships between a quantifiable 
measure of small airways disease and physiological measures 
of small airway function to be determined for the first time.
Assessing therapeutic response
When assessing the effects of therapy in COPD (eg, bron-
chodilators) for general clinical management or clinical 
trials, spirometric parameters (particularly the FEV
1
) are 
usually the primary outcome. However, spirometry has a 
number of limitations, particularly in COPD where airflow 
obstruction often tends to be “fixed”. It is well documented 
that bronchodilators can improve airway caliber (hence 
ventilation) over the tidal breathing range in COPD, leading 
to reduced hyperinflation, reduced work of breathing and 
symptomatic improvement in the absence of a significant 
spirometric response.96
The ability of small airways tests to detect physiological 
change following bronchodilation with greater sensitivity 
than spirometry has been robustly demonstrated in both 
asthma97 and COPD.98 Most notably in COPD, IOS measures 
of R5 and X5 and also plethysmographic Raw and sGaw 
Table 1 Methodologies to assess small airways function
Test Strengths Weaknesses Change in COPD
Expiratory flows 1. Nonspecialized kit
2. widely available
3. Integral to spirometry
1. Highly effort dependent
2. Results variable
3. wide “normal” range
4. Requires careful interpretation
↓ MMeF, ↓ MeF25
Single breath washout 1. Overall assessment of ventilation 
heterogeneity (Phase III slope)
2. Quick to perform
3. Novel double tracer gas method 
requires only tidal breathing
1. Classical method is effort dependent
2. Cv may be less informative about small airways
3. Double tracer gas method not fully validated
↑ Phase III slope
↑ Cv, ↑ CC
Multiple breath washout 1. Assessment of acinar and small 
conducting airway ventilation
2. effort independent
3. evidence suggests that it is 
sensitive to detection of early 
disease
1. Time consuming
2. Results can be variable
3. Different tracer gases yield different results
4. Limited information on normal range for older 
adults
↑ LCI, ↑ Scond, ↑ Sacin
Plethysmography 1. sRaw is effort independent
2. Quick test
1. Achievement of TGv for Raw derivation can be 
technically demanding
2. Not specific to small airway function
3. Sensitivity to early disease disputable
↑ Raw, ↑ sRaw, ↓ sGaw
Oscillometry 1. Quick and effort independent
2. Robust normal range
3. Specific to small airway function 
(particularly new FOT systems)
4. Clinically validated – many 
studies support usefulness
1. Specialized equipment early: ↓ X5 only
Advanced: ↑ R5 and ↓ X5
CT 1. Allows direct quantification of 
the presence of disease
2. Gold standard for identifying and 
quantifying emphysema
3. Preliminary studies of inspiratory/
expiratory CT offer promise
1. exposure to radiation prohibits regular 
assessment
2. expensive
3. Requires specialist centers and analysis
4. Achieving consistent RV is difficult
5. Inspiratory/expiratory method not fully validated
Areas of low density at 
TLC indicate emphysema
Additional areas of low 
density at Rv indicate 
small airways disease
Notes: The table illustrates the different techniques currently available to assess small airways function and their strengths and weaknesses as well as pattern of change 
classically seen in COPD. 
Abbreviations: CC, closing capacity; CV, closing volume; FOT, forced oscillometry technique; LCI, lung clearance index; MMEF, maximal mid-expiratory flow; Raw, 
airway resistance; MeF25, maximal expiratory flow when 25% of forced vital capacity remains; Scond, conductive airway heterogeneity; Sacin, acinar airway heterogeneity; X5, 
reactance at 5 Hz; R5, resistance at 5 Hz; RV, residual volume; sGaw, specific airway conductance; sRaw, specific airway resistance; TGV, thoracic gas volume; TLC, total 
lung capacity.
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showed higher sensitivity (accounting for within-test and 
day-to-day variabilities) to salbutamol response, than FEV
1
. 
Improvements in airways resistance (R5 and Raw) are due to 
an increase in airway caliber. The reason for improved lung 
reactance (X5) is less apparent but may be due to reduced 
hyperinflation following bronchodilation of the small air-
ways and a consequent improvement in lung compliance. 
MMEF was also assessed but only showed an improvement 
at higher doses, which was then lost at subsequent doses. 
The variability in MMEF may be due to changes in FVC 
following bronchodilation, which can cause MMEF to shift. 
For this reason, it may be more useful to adjust MMEF for 
lung volume when assessing therapeutic response, as men-
tioned previously.21,22
The clinical usefulness of assessing bronchodilator 
response in early COPD is debatable, as current guidelines 
generally recommend the commencement of bronchodilators 
once physiologically established COPD has developed.14 
However, it is important to appreciate that spirometry is 
limited and tests of small airways function may be a more 
sensitive and robust method of detecting physiological 
change than FEV
1
, particularly in clinical trials.
Summary and conclusion
There is increasing recognition that diagnosing lung dis-
eases in the earliest stages may offer valuable insight into 
pathogenesis and provide a better opportunity to intervene 
in the natural history of the disease, thus improving long-
term patient outcomes. Both physiological and pathological 
studies suggest that small airways damage and dysfunction 
may precede airflow obstruction and emphysema and may, 
therefore, provide a signal of early disease in COPD.
The assessment of small airways physiology is not a 
new concept, and over time, a number of methodologies 
have emerged that have sought to provide information about 
small airways function. These are summarized in Table 1, 
which also describes the potential strengths and limitations 
of each approach.
Historically, it has proven difficult to obtain specific 
measurements of small airway function and, consequently, 
available techniques had been largely abandoned for general 
clinical management (where disease is usually well estab-
lished). However, as Table 1 summarizes, new methods as 
well as improved technologies for existing tests have recently 
emerged that may prove more useful especially in the iden-
tification of early disease before the spirometric criterion 
defining COPD is reached. Certainly, some of these physi-
ological tests have demonstrated a degree of usefulness both 
clinically and as research tools to answer or explore several 
pathophysiological questions. If these methods can ultimately 
prove sensitive to small airways dysfunction and progressive 
lung damage, they may aid the diagnosis of early disease (pre-
COPD) and also potentially improve the ability to monitor, 
prevent or abrogate long-term clinical outcomes.
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